PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update

Description:
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update

Summary

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi's Menactra and Novartis' Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape, and an increase in the coverage rates of existing routine vaccination programs. Cost-effectiveness concerns, especially for serogroup B vaccines, will serve as a key barrier to market growth. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

Highlights

Key Questions Answered

- How large an impact will serotype B vaccines have on the meningococcal market? What do key opinion leaders think of these vaccines?
- What are the key vaccines for each age segment and country?
- Which meningococcal vaccines will face adoption challenges in the market? What is the projected uptake of new vaccines, such as Novartis' Bexsero, over the forecast period?
- The developmental pipeline consists of vaccines that address serotype B protection and immunogenicity in infants. Which of these vaccines will attain high sales revenues during 2012-2022 and in which markets?
- What governmental and industry developments are likely to affect the vaccination rates in the markets researched? Which is the largest growth market globally?

Key Findings

- Country-specific epidemiology and serotype distributions heavily influence immunization recommendations and vaccine usage.
- The potential impact of serogroup B vaccines on the marketplace will be determined by their inclusion in routine vaccination programs.
- Major players will leverage their R&D, manufacturing, and distribution networks to maintain their stakes in the market.
- Government endorsements of new and existing vaccines, in particular serogroup B vaccines, are anticipated to dramatically influence market growth.

Scope

- Overview of meningococcal disease, including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines.
- Annualized meningococcal vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the meningococcal vaccine market.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically serotype B vaccines and early stage infant and pentavalent vaccines.
- Analysis of the current and future market competition in the global meningococcal vaccine market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the meningococcal vaccine market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global meningococcal vaccine market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global meningococcal vaccine market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Contents:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.2.1 Infants and Young Children are at Greatest Risk for Developing Meningococcal Disease
4.2.2 Direct Contact and Overcrowding are the Primary Risk Factors for Infection
4.2.3 Exposure is Highest for Those Traveling to the African “Meningitis Belt”
4.3 Global Trends
4.3.1 US
4.3.2 EU
4.3.3 Australia
4.3.4 Brazil
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiology Forecast of Meningococcal Disease (2012-2022)
4.5.1 Incident Cases of Meningococcal Disease
4.5.2 Age-Specific Incident Cases of Meningococcal Disease
4.5.3 Incident Cases of Meningococcal Disease By Serogroup
4.6 Discussion
4.6.1 Conclusions on Epidemiological Trends
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Meningococcal Immunization Policy
5.2 US
5.2.1 Meningococcal Immunization Recommendations and Policies
5.2.2 Clinical Practice
5.3 France
5.3.1 Meningococcal Immunization Recommendations and Policies
5.3.2 Clinical Practice
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
  9.3.1 Sanofi
  9.3.2 Novartis
  9.3.3 GlaxoSmithKline
  9.3.4 Baxter
  9.3.5 Nuron Biotech
  9.3.6 Pfizer
10 Market Outlook
  10.1 Global Markets
    10.1.1 Forecast
    10.1.2 Drivers and Barriers - Global Issues
  10.2 United States
    10.2.1 Forecast
    10.2.2 Key Events
    10.2.3 Drivers and Barriers
  10.3 France
    10.3.1 Forecast
    10.3.2 Key Events
    10.3.3 Drivers and Barriers
  10.4 Germany
    10.4.1 Forecast
    10.4.2 Key Events
    10.4.3 Drivers and Barriers
  10.5 Italy
    10.5.1 Forecast
    10.5.2 Key Events
    10.5.3 Drivers and Barriers
  10.6 Spain
    10.6.1 Forecast
    10.6.2 Key Events
    10.6.3 Drivers and Barriers
  10.7 United Kingdom
    10.7.1 Forecast
    10.7.2 Key Events
    10.7.3 Drivers and Barriers
  10.8 Japan
    10.8.1 Drivers and Barriers
  10.9 Australia
    10.9.1 Forecast
    10.9.2 Key Events
    10.9.3 Drivers and Barriers
  10.10 Brazil
    10.10.1 Forecast
    10.10.2 Key Events
    10.10.3 Drivers and Barriers
11 Appendix
  11.1 Bibliography
  11.2 Abbreviations
  11.3 Methodology
  11.4 Forecasting Methodology
    11.4.1 Vaccine Coverage
    11.4.2 Vaccine Approval vs. Routine Schedule Inclusion
    11.4.3 Vaccines Included
    11.4.4 Key Launch Dates
    11.4.5 General Pricing Assumptions
    11.4.6 Individual Vaccine Assumptions
    11.4.7 Pricing of Pipeline agents
  11.5 Physicians and Specialists Included in this Study
  11.6 About the Authors
    11.6.1 Authors
11.6.2 Reviewers
11.6.3 Epidemiologists
11.6.4 Global Head of Healthcare
11.7 About Us
11.8 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Meningococcal Disease
Table 2: Risk Factors for Meningococcal Disease
Table 3: Sources of Incidence Data Used in the Epidemiology Forecast
Table 4: 8MM, Incident Cases of Meningococcal Disease, N, Select Years, 2012-2022
Table 5: 8MM, Incident Cases of Meningococcal Disease, By Age, N (Row %), 2012
Table 6: 8MM, Incident Cases of Meningococcal Disease, By Serogroup, N (Row %), 2012
Table 7: Meningococcal Immunization Recommendation Agencies by Country
Table 8: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012
Table 9: Leading Vaccines for Meningococcal Disease, 2012
Table 10: Product Profile - Menactra
Table 11: Menactra SWOT Analysis, 2012
Table 12: Global Sales Forecasts ($m) for Menactra, 2012-2022
Table 13: Product Profile - Mencevo
Table 14: Mencevo SWOT Analysis, 2012
Table 15: Global Sales Forecasts ($m) for Mencevo, 2012-2022
Table 16: Product Profile - Nimenrix
Table 17: Nimenrix SWOT Analysis, 2012
Table 18: Global Sales Forecasts ($m) for Nimenrix, 2012-2022
Table 19: Product Profile - MenHibrix
Table 20: MenHibrix SWOT Analysis, 2012
Table 21: Global Sales Forecasts ($m) for MenHibrix, 2012-2022
Table 22: Product Profile - Menitorix
Table 23: Menitorix SWOT Analysis, 2012
Table 24: Global Sales Forecasts ($m) for Menitorix, 2012-2022
Table 25: Product Profile - Meningitec
Table 26: Meningitec SWOT Analysis, 2012
Table 27: Global Sales Forecasts ($m) for Meningitec, 2012-2022
Table 28: Product Profile - Menjugate
Table 29: Menjugate SWOT Analysis, 2012
Table 30: Global Sales Forecasts ($m) for Menjugate, 2012-2022
Table 31: Product Profile - NeisVac-C
Table 32: NeisVac-C SWOT Analysis, 2012
Table 33: Global Sales Forecasts ($m) for NeisVac-C, 2012-2022
Table 34: Product Profile - Menomune
Table 35: Menomune SWOT Analysis, 2012
Table 36: Global Sales Forecasts ($m) for Menomune, 2012-2022
Table 37: Product Profile - Bexsero
Table 38: Bexsero SWOT Analysis, 2012
Table 39: Global Sales Forecasts ($m) for Bexsero, 2012-2022
Table 40: Overall Unmet Needs - Current Level of Attainment
Table 41: Clinical Unmet Needs - Gap Analysis, 2012
Table 42: Meningococcal Vaccines - Clinical Trials by Phase and Status, 2012
Table 43: Meningococcal Vaccines - Phase Pipeline, 2012
Table 44: Comparison of Vaccines in Development for Meningococcal Disease, 2012
Table 45: Product Profile - MnB rLP2086
Table 46: MnB rLP2086 SWOT Analysis, 2012
Table 47: Global Sales Forecasts ($m) for MnB rLP2086, 2012-2022
Table 48: Product Profile - Meninge ACYW conj.
Table 49: Meninge ACYW conj. SWOT Analysis, 2012
Table 50: Product Profile - MenABCWY
Table 51: MenABCWY SWOT Analysis, 2012
Table 52: Product Profile - MenC conjugate
Table 53: MenC conjugate SWOT Analysis, 2012
Table 54: Product Profile - Heptavalent DTP-Hib-HepB-IPV-MenC
Table 56: Key Companies in the Meningococcal Vaccines Market, 2012
Table 57: Sanofi's Meningococcal Vaccines Portfolio Assessment, 2012
Table 58: Sanofi SWOT Analysis, 2012
Table 59: Novartis' Meningococcal Vaccines Portfolio Assessment, 2012
Table 60: Novartis SWOT Analysis, 2012
Table 61: GSK's Meningococcal Vaccines Portfolio Assessment, 2012
Table 62: GSK SWOT Analysis, 2012
Table 63: Baxter's Meningococcal Vaccines Portfolio Assessment, 2012
Table 64: Baxter SWOT Analysis, 2012
Table 65: Nuron Biotech's Meningococcal Vaccines Portfolio Assessment, 2012
Table 66: Nuron Biotech SWOT Analysis, 2012
Table 67: Pfizer's Meningococcal Vaccines Portfolio Assessment, 2012
Table 68: Pfizer SWOT Analysis, 2012
Table 69: Global Sales Forecasts ($m) for Meningococcal Vaccines, 2012-2022
Table 70: Global Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 71: Sales Forecasts ($m) for Meningococcal Vaccines in the United States, 2012-2022
Table 72: Key Events Impacting Sales for Meningococcal Vaccines in US, 2012
Table 73: United States Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 74: Sales Forecasts ($m) for Meningococcal Vaccines in France, 2012-2022
Table 75: Key Events Impacting Sales for Meningococcal Vaccines in France, 2012-2022
Table 76: France Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 77: Sales Forecasts ($m) for Meningococcal Vaccines in Germany, 2012-2022
Table 78: Key Events Impacting Sales for Meningococcal Vaccines in Germany, 2012-2022
Table 79: Germany Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 80: Sales Forecasts ($m) for Meningococcal Vaccines in Italy, 2012-2022
Table 81: Key Events Impacting Sales for Meningococcal Vaccines in Italy, 2012-2022
Table 82: Italy Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 83: Sales Forecasts ($m) for Meningococcal Vaccines in Spain, 2012-2022
Table 84: Key Events Impacting Sales for Meningococcal Vaccines in Spain, 2012-2022
Table 85: Spain Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 86: Sales Forecasts ($m) for Meningococcal Vaccines in the United Kingdom, 2012-2022
Table 87: Key Events Impacting Sales for Meningococcal Vaccines in UK, 2012-2022
Table 88: United Kingdom Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 89: Japan Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 90: Sales Forecasts ($m) for Meningococcal Vaccines in Australia, 2012-2022
Table 91: Key Events Impacting Sales for Meningococcal Vaccines in Australia, 2012-2022
Table 92: Australia Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 93: Sales Forecasts ($m) for Meningococcal Vaccines in Brazil, 2012-2022
Table 94: Key Events Impacting Sales for Meningococcal Vaccines in Brazil, 2012-2022
Table 95: Brazil Meningococcal Vaccines Market - Drivers and Barriers, 2012-2022
Table 96: Key Launch Dates
Table 97: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Membrane Structure of N. meningitidis
Figure 2: 8MM, Incident Cases of Meningococcal Disease, N, Select Years, 2012-2022
Figure 3: 8MM, Incident Cases of Meningococcal Disease, By Age, N, 2012
Figure 4: 8MM, Incident Cases of Meningococcal Disease, By Serogroup, %, 2012
Figure 5: Meningococcal Vaccines - Clinical Trials by Country, 2012
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in Meningococcal Vaccines, 2012-2022
Figure 7: Company Portfolio Gap Analysis in Meningococcal Vaccines, 2012-2022
Figure 8: Global Sales for Meningococcal Vaccines by Region, 2012-2022
Figure 9: Sales for Meningococcal Vaccines in the United States by Vaccine Class, 2012-2022
Figure 10: Sales for Meningococcal Vaccines in France by Vaccine Class, 2012-2022
Figure 11: Sales for Meningococcal Vaccines in Germany by Vaccine Class, 2012-2022
Figure 12: Sales for Meningococcal Vaccines in Italy by Vaccine Class, 2012-2022
Figure 13: Sales for Meningococcal Vaccines in Spain by Vaccine Class, 2012-2022
Figure 14: Sales for Meningococcal Vaccines in the United Kingdom by Vaccine Class, 2012-2022
Figure 15: Sales for Meningococcal Vaccines in Australia by Vaccine Class, 2012-2022
Figure 16: Sales for Meningococcal Vaccines in Brazil by Vaccine Class, 2012-2022
Ordering:

Order Online - [http://www.researchandmarkets.com/reports/2762058/](http://www.researchandmarkets.com/reports/2762058/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update
Web Address: http://www.researchandmarkets.com/reports/2762058/
Office Code: SCH3Q6RY

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 10995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 21990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 32985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr  □  Mrs  □  Dr  □  Miss  □  Ms  □  Prof  □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World